JP Morgan downgraded Rallybio from Overweight to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/9/2025 | Buy → Neutral | H.C. Wainwright | |
| 5/15/2024 | Overweight → Neutral | JP Morgan | |
| 2/7/2024 | $7.00 → $1.50 | Buy → Hold | Jefferies |
| 4/17/2023 | $18.00 | Buy | H.C. Wainwright |
| 4/10/2023 | $17.00 | Outperform | Wedbush |
| 12/9/2022 | $21.00 | Overweight | JP Morgan |
| 2/22/2022 | $32.00 | Mkt Outperform | JMP Securities |
| 8/23/2021 | $40.00 | Outperform | Evercore ISI Group |
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
8-K - Rallybio Corp (0001739410) (Filer)
8-K - Rallybio Corp (0001739410) (Filer)
S-8 - Rallybio Corp (0001739410) (Filer)
H.C. Wainwright downgraded Rallybio from Buy to Neutral
JP Morgan downgraded Rallybio from Overweight to Neutral
Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously
– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome – – Data Readouts Expected from Cohort 1 in 3Q 2025 and Cohort 2 in 4Q 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor. Additionally, Rallybio announced t
– On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 – – $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2025 Provides Runway into 1H 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments. "We are focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study this quarter, and believe th
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025 at 12:00 p.m. ET in New York, NY. A live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio's website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation. About Rallybio Rallybio (NASDAQ:RLYB) is a clinical-stage bi